July 15, 2021 -- Sana Biotechnology has signed a lease to develop a 163,000-sq-ft manufacturing facility in Fremont, CA, to support the manufacture of its late-stage clinical development and early commercial cell and gene therapy (CGT) candidates.
The facility will be designed to provide manufacturing capabilities across the company's portfolio, including allogeneic T cell, viral vector, and pluripotent stem cell production.
The facility's location is in close proximity to Sana's existing technical and scientific capabilities, the firm said. Sana also intends to work with contract manufacturing partners to advance its candidates to the clinic as early as next year.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
